NICE guidance on omalizumab for severe asthma

Diaz, Richard A; Charles, Zoe; George, Elisabeth; Adler, Amanda I

doi:10.1016/s2213-2600(13)70066-3

Cited by 13 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical stopping rules should be developed for AIT, similarly to what is currently considered for biologics in severe asthma, as a guidance for continuing or stopping treatment after a short (early stopping rule) or long (late stopping rule) period. As an example, a global treatment evaluation after 16 weeks is used as an early stopping rule for omalizumab treatment (49,50).…”

Section: Accepted Articlementioning

confidence: 99%

2019 ARIA Care pathways for allergen immunotherapy

Bousquet¹,

Pfaar²,

Togias³

et al. 2019

Alergologia

View full text Add to dashboard Cite

Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many guidelines or national practice guidelines have been produced but the evidencebased method varies, many are complex and none propose care pathways. This paper reviews care pathways for AIT using strict criteria and provides simple recommendations that can be used by all stakeholders including health professionals. The decision to prescribe AIT for the patient should be individualized and based on the relevance of the allergens, the persistence of symptoms despite appropriate medications according to guidelines as well as on the availability of good-quality and efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by specialists for stratified patients. There are no currently available validated biomarkers that can predict AIT success. In adolescents and adults, AIT should be reserved for patients with moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except in some specific cases. Immunotherapy may be even more advantageous in patients with multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are promising for the stratification and follow up of patients.

show abstract

Section: Accepted Articlementioning

confidence: 99%

2019 ARIA Care pathways for allergen immunotherapy

Bousquet¹,

Pfaar²,

Togias³

et al. 2019

Alergologia

View full text Add to dashboard Cite

show abstract

“…In the Global Initiative for Asthma (GINA) strategy, omalizumab, mepolizumab and reslizumab represent the first (and, currently, only) therapies for severe asthma (step 5) (data sourced from GINA: ginasthma.org). The National Institute for Health and Care Excellence, UK (NICE) proposed alternative guidance for omalizumab in 2013 [17], reviewed in 2016, and for mepolizumab and reslizumab in 2017 (table 1).…”

Section: From Guidelines To Care Pathwaysmentioning

confidence: 99%

Care pathways for the selection of a biologic in severe asthma

Bousquet

Brusselle

Buhl³

et al. 2017

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…Existing therapies, available beyond step 5 asthma, include Omalizumab, which is used for a specific sub-group of allergic patients who meet the National Institute for Clinical Excellence (NICE) guidelines criteria. 16 This is an example of a therapy that has emerged from research over the last 10 years to change the management for a small proportion (estimated between 10% and 15%) 17 of all patients with severe asthma. Recent real-life studies, both in the UK and internationally, have demonstrated that, in clinical practice, the observed benefits and response rates (approximately 70%) are higher than was experienced during clinical trials.…”

Section: Existing Approaches Used At or Beyond Stepmentioning

confidence: 99%

Refractory asthma – beyond step 5, the role of new and emerging adjuvant therapies

2014

View full text Add to dashboard Cite

A small percentage of asthmatics have 'severe refractory asthma', where there is suboptimal response to currently available therapies. A number of novel therapies targeting key biological targets are becoming available. Asthma is a heterogeneous disease, and systematic evaluation of patients is important to target therapies to the underlying inflammatory subtype and clinical features. This review article outlines new and emerging treatments for severe asthma, including monoclonal antibodies targeting eosinophilic disease, anti-neutrophil strategies, novel bronchodilators and bronchial thermoplasty. We highlight the importance of individualized investigation, treatment and management of severe asthmatics.

show abstract

NICE guidance on omalizumab for severe asthma

Cited by 13 publications

References 2 publications

2019 ARIA Care pathways for allergen immunotherapy

2019 ARIA Care pathways for allergen immunotherapy

Care pathways for the selection of a biologic in severe asthma

Refractory asthma – beyond step 5, the role of new and emerging adjuvant therapies

Contact Info

Product

Resources

About